Compare Recursion Pharmaceuticals Inc (RXRX) vs Tesla, Inc. (TSLA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Recursion Pharmaceuticals Inc vs Tesla, Inc. — how do they compare? Recursion Pharmaceuticals Inc trades at $3.33 (market cap $1.78B), while Tesla, Inc. trades at $332.85 (market cap $1.31T). The key difference: Tesla, Inc. is far larger — about 736× Recursion Pharmaceuticals Inc's market cap. Which is the better fit depends on your goals.
| RXRX | TSLA | |
|---|---|---|
Market Cap | $1.78B | $1.31T |
Sector | Health | Consumer Cyclical |
52-Week High | $6.79 | $489.88 |
52-Week Low | $2.84 | $298.16 |
Enterprise Value | $1.30B | $1.28T |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RXRX trades at $3.22, up 1.26% today, with a neutral technical signal and bearish moving averages. The company reported a Q2 2026 EPS miss of -$0.25 versus -$0.24 expected, with revenue declining year-over-year. Financials show steep losses, including a net income margin of -961.97% in 2026, though cash flow from financing activities provides a runway through early 2028. Recent news highlights partnership progress with Genentech but notes competitive pressures and slow revenue growth.
Outlook remains speculative due to high cash burn and unproven commercial scalability, posing significant risk. Analyst consensus is mixed with 40% buy ratings, reflecting optimism for AI-driven drug discovery potential against persistent profitability challenges. Investment appeal hinges on pipeline milestones, but current fundamentals warrant caution.
Tesla (TSLA) trades at $330.87, up 0.7% today, amid mixed signals: technicals are bearish with support at $327 and resistance at $333, while fundamentals show elevated valuation ratios (P/E 306.37) but recent earnings beats. Revenue dipped to $94.83B in 2025, with net margin at 3.67%, as the company pivots toward AI and robotics. News highlights regulatory approval for self-driving software in Europe (Reuters, 2026-04-10) and a 315% surge in German registrations (Zacks, 2026-04-10).
Outlook: Tesla's stock faces headwinds from high valuation and slowing auto growth, but opportunities exist in AI and energy expansion. Risks include intense EV competition and execution challenges. Analysts are divided, with a consensus price target of $393.87 (40.74% buy ratings), suggesting cautious optimism if innovation delivers.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →About Tesla, Inc.
Tesla Inc. designs, manufactures, and sells high-performance electric vehicles and electric vehicle powertrain components. The Company owns its sales and service network and sells electric power train components to other automobile manufacturers. Tesla serves customers worldwide.
Read more on TSLA →
